UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis

BMJ open gastroenterology, 2021-08, Vol.8 (1), p.e000680

2021

Volltextzugriff (PDF)

Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers

Pharmacology research & perspectives, 2017-12, Vol.5 (6), p.n/a

2017

Volltextzugriff (PDF)

Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: Results of two randomized studies in patients with Parkinson's disease

Clinical therapeutics, 2007-12, Vol.29 (12), p.2654-2666

2007

Volltextzugriff (PDF)

The Effects of Ethanol on the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Ezogabine (Retigabine)

Clinical therapeutics, 2013, Vol.35 (1), p.87-93

2013

Volltextzugriff (PDF)

Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab

Journal of pharmacokinetics and pharmacodynamics, 2024-06, Vol.51 (3), p.289-301

2024

Volltextzugriff (PDF)

Efficacy and Tolerability Exposure–Response Relationship of Retigabine (Ezogabine) Immediate-Release Tablets in Patients With Partial-Onset Seizures

Clinical therapeutics, 2013-08, Vol.35 (8), p.1174-1185.e4

2013

Volltextzugriff (PDF)

Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772

Pharmaceutical research, 2021-07, Vol.38 (7), p.1235-1245

2021

Volltextzugriff (PDF)

Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects

European journal of drug metabolism and pharmacokinetics, 2021-01, Vol.46 (1), p.71-83

2021

Volltextzugriff (PDF)

The effect of ezogabine on the pharmacokinetics of an oral contraceptive agent

International journal of clinical pharmacology and therapeutics, 2013-11, Vol.51 (11), p.847-853

2013

Volltextzugriff (PDF)

Adolescent Clinical Development of Ezogabine/Retigabine as Adjunctive Therapy for Partial-Onset Seizures: Pharmacokinetics and Tolerability

The journal of pediatric pharmacology and therapeutics, 2016-09, Vol.21 (5), p.404-412

2016

Volltextzugriff (PDF)

Steady‐state Pharmacokinetics of Lamotrigine when Converting from a Twice‐daily Immediate‐release to a Once‐daily Extended‐release Formulation in Subjects with Epilepsy (The COMPASS Study)

Epilepsia (Copenhagen), 2008-03, Vol.49 (3), p.410-417

2008

Volltextzugriff (PDF)

Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug-drug interaction study

Clinical pharmacology: advances and applications, 2014-01, Vol.6 (default), p.149-159

2014

Volltextzugriff (PDF)

Clinical pharmacokinetics of retigabine/ezogabine

Current clinical pharmacology, 2013-01, Vol.8 (4), p.319-331

2013

Volltextzugriff (PDF)

Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK 1 inhibitor GSK 2982772 in healthy volunteers

Pharmacology research & perspectives, 2017-12, Vol.5 (6)

2017

Volltextzugriff (PDF)

The interaction potential of retigabine (ezogabine) with other antiepileptic drugs

Current clinical pharmacology, 2014-05, Vol.9 (2), p.148-156

2014

Volltextzugriff (PDF)

Effect of hemodialysis on pharmacokinetics of ezogabine/retigabine and its N-acetyl metabolite in patients with end stage renal disease

Current clinical pharmacology, 2014-01, Vol.9 (4), p.319-325

2014

Volltextzugriff (PDF)

Results of the First U.S. Double-Blind, Placebo-Controlled, Multicenter Clinical Study in Asthma with Pranlukast, a Novel Leukotriene Receptor Antagonist

The Journal of asthma, 1997, Vol.34 (4), p.321-328

1997

Volltextzugriff (PDF)

Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study

Journal of neurology, 2017-02, Vol.264 (2), p.304-315

2017

Volltextzugriff (PDF)

Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Dermatology and therapy, 2024-02, Vol.14 (2), p.489-504

2024

Volltextzugriff (PDF)

A novel design for a dose finding, safety, and drug interaction study of an antiepileptic drug (retigabine) in early clinical development

International journal of clinical pharmacology and therapeutics, 2014-06, Vol.52 (6), p.509-518

2014

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(17)
Mit Volltextzugriff
(15)

Publikationsform

Artikel
(20)

Sprache

Englisch
(20)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis

Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers

Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: Results of two randomized studies in patients with Parkinson's disease

The Effects of Ethanol on the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Ezogabine (Retigabine)

Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab

Efficacy and Tolerability Exposure–Response Relationship of Retigabine (Ezogabine) Immediate-Release Tablets in Patients With Partial-Onset Seizures

Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772

Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects

The effect of ezogabine on the pharmacokinetics of an oral contraceptive agent

Adolescent Clinical Development of Ezogabine/Retigabine as Adjunctive Therapy for Partial-Onset Seizures: Pharmacokinetics and Tolerability

Steady‐state Pharmacokinetics of Lamotrigine when Converting from a Twice‐daily Immediate‐release to a Once‐daily Extended‐release Formulation in Subjects with Epilepsy (The COMPASS Study)

Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug-drug interaction study

Clinical pharmacokinetics of retigabine/ezogabine

Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK 1 inhibitor GSK 2982772 in healthy volunteers

The interaction potential of retigabine (ezogabine) with other antiepileptic drugs

Effect of hemodialysis on pharmacokinetics of ezogabine/retigabine and its N-acetyl metabolite in patients with end stage renal disease

Results of the First U.S. Double-Blind, Placebo-Controlled, Multicenter Clinical Study in Asthma with Pranlukast, a Novel Leukotriene Receptor Antagonist

Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study

Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

A novel design for a dose finding, safety, and drug interaction study of an antiepileptic drug (retigabine) in early clinical development

Suchergebnisse filtern